WO2015006337A3 - Compositions and methods for increasing protein half-life in a serum - Google Patents

Compositions and methods for increasing protein half-life in a serum Download PDF

Info

Publication number
WO2015006337A3
WO2015006337A3 PCT/US2014/045768 US2014045768W WO2015006337A3 WO 2015006337 A3 WO2015006337 A3 WO 2015006337A3 US 2014045768 W US2014045768 W US 2014045768W WO 2015006337 A3 WO2015006337 A3 WO 2015006337A3
Authority
WO
WIPO (PCT)
Prior art keywords
serum
compositions
life
methods
increasing protein
Prior art date
Application number
PCT/US2014/045768
Other languages
French (fr)
Other versions
WO2015006337A2 (en
Inventor
Fang Liang Zhang
Jianbing Zhang
Shu Wu
Original Assignee
Nanjingjinsirui Science & Technology Biology Corporation
Genscript Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjingjinsirui Science & Technology Biology Corporation, Genscript Corporation filed Critical Nanjingjinsirui Science & Technology Biology Corporation
Priority to EP14822180.7A priority Critical patent/EP3019192A4/en
Priority to JP2016525430A priority patent/JP6449272B2/en
Priority to US14/903,156 priority patent/US10407508B2/en
Priority to CN201480038652.2A priority patent/CN105555310B/en
Publication of WO2015006337A2 publication Critical patent/WO2015006337A2/en
Publication of WO2015006337A3 publication Critical patent/WO2015006337A3/en
Priority to US16/458,872 priority patent/US11168146B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Novel antibodies, such as single domain antibodies (sdAbs), or fragments thereof that specifically bind a transferrin are described. Compositions, methods and systems for increasing the half-life of a target protein in a serum using an antibody or fragment thereof against a transferrin are described.
PCT/US2014/045768 2013-07-08 2014-07-08 Compositions and methods for increasing protein half-life in a serum WO2015006337A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP14822180.7A EP3019192A4 (en) 2013-07-08 2014-07-08 Compositions and methods for increasing protein half-life in a serum
JP2016525430A JP6449272B2 (en) 2013-07-08 2014-07-08 Compositions and methods for increasing the serum half-life of proteins
US14/903,156 US10407508B2 (en) 2013-07-08 2014-07-08 Compositions and methods for increasing protein half-life in a serum
CN201480038652.2A CN105555310B (en) 2013-07-08 2014-07-08 A kind of composition and method improving albumen serum half-life
US16/458,872 US11168146B2 (en) 2013-07-08 2019-07-01 Compositions and methods for increasing protein half-life in a serum

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361843628P 2013-07-08 2013-07-08
US61/843,628 2013-07-08

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/903,156 A-371-Of-International US10407508B2 (en) 2013-07-08 2014-07-08 Compositions and methods for increasing protein half-life in a serum
US16/458,872 Division US11168146B2 (en) 2013-07-08 2019-07-01 Compositions and methods for increasing protein half-life in a serum

Publications (2)

Publication Number Publication Date
WO2015006337A2 WO2015006337A2 (en) 2015-01-15
WO2015006337A3 true WO2015006337A3 (en) 2015-10-29

Family

ID=52280705

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/045768 WO2015006337A2 (en) 2013-07-08 2014-07-08 Compositions and methods for increasing protein half-life in a serum

Country Status (5)

Country Link
US (2) US10407508B2 (en)
EP (1) EP3019192A4 (en)
JP (1) JP6449272B2 (en)
CN (1) CN105555310B (en)
WO (1) WO2015006337A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3325512B1 (en) 2015-07-23 2023-09-06 Inhibrx, Inc. Multivalent and multispecific gitr-binding fusion proteins
CA3022494A1 (en) * 2016-05-01 2017-11-09 Ucb Biopharma Sprl Affinity engineered serum protein carrier binding domain
JP2021500856A (en) * 2017-09-13 2021-01-14 江蘇恒瑞医薬股▲ふん▼有限公司 IL-6R antibody and its antigen-binding fragment and its use as a drug
JP7189211B2 (en) * 2017-10-11 2022-12-13 ナンジン レジェンド バイオテック カンパニー，リミテッド Compositions and methods for increasing protein half-life in serum
EP3553082A1 (en) * 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Brain natriuretic peptide engrafted antibodies
CN117377487A (en) * 2021-12-02 2024-01-09 领诺(上海)医药科技有限公司 Transferrin binding antibodies and uses thereof
WO2023142109A1 (en) * 2022-01-30 2023-08-03 领诺(上海)医药科技有限公司 Long-acting recombinant human growth hormone and use thereof
WO2023207574A1 (en) * 2022-04-28 2023-11-02 领诺(上海)医药科技有限公司 Recombinant harsa for crossing blood-brain barrier

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555114B1 (en) * 1993-11-04 2003-04-29 Innogenetics N.V. Immunodominant human T-cell epitopes of hepatitis C virus
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
US7250166B2 (en) * 2001-01-12 2007-07-31 Molecules Of Man Ab Human monoclonal antibodies that bind hepatitis C virus (HCV) E1
WO2007120864A2 (en) * 2006-04-14 2007-10-25 Shire Llc Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse
WO2009059972A2 (en) * 2007-11-05 2009-05-14 Nordic Bioscience A/S Biochemical markers for cvd risk assessment
US20100310464A1 (en) * 2009-06-09 2010-12-09 Affitech Research As Antibodies
US20110262427A1 (en) * 2006-12-15 2011-10-27 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
US8101393B2 (en) * 2006-02-10 2012-01-24 Bp Corporation North America Inc. Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
US8147836B2 (en) * 2007-12-17 2012-04-03 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising MMP-14 binding proteins
US8349326B2 (en) * 2007-02-20 2013-01-08 Tufts University Methods and systems for multi-antibody therapies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070031440A1 (en) * 2001-08-30 2007-02-08 Prior Christopher P Modified transferin-antibody fusion proteins
US20110092677A1 (en) * 2001-08-30 2011-04-21 Biorexis Technology, Inc. Modified transferin-antibody fusion proteins
US20060130158A1 (en) * 2002-08-30 2006-06-15 Turner Andrew J Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
CA2505325C (en) 2002-11-08 2014-02-25 Ablynx N.V. Stabilized single domain antibodies
AU2005250216B2 (en) * 2004-06-01 2009-12-10 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
KR101323563B1 (en) * 2005-10-18 2013-10-29 니토 보세키 가부시기가이샤 Antibody-producing transgenic silkworms and methods for producing the same
WO2008145141A1 (en) * 2007-05-31 2008-12-04 Genmab A/S Method for extending the half-life of exogenous or endogenous soluble molecules
JP5592792B2 (en) * 2007-09-26 2014-09-17 ユセベ ファルマ ソシエテ アノニム Bispecific antibody fusions
AP2012006359A0 (en) 2010-03-03 2012-08-31 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
WO2013071127A1 (en) * 2011-11-09 2013-05-16 Alper Biotech, Llc Monoclonal antibodies against serotransferrin antigens, and uses therefor
US9611301B2 (en) * 2012-03-20 2017-04-04 The University Of Iowa Research Foundation GB virus C (hepatitis G virus) E2 glycoprotein as an immunomodulatory agent

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555114B1 (en) * 1993-11-04 2003-04-29 Innogenetics N.V. Immunodominant human T-cell epitopes of hepatitis C virus
US7250166B2 (en) * 2001-01-12 2007-07-31 Molecules Of Man Ab Human monoclonal antibodies that bind hepatitis C virus (HCV) E1
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
US8101393B2 (en) * 2006-02-10 2012-01-24 Bp Corporation North America Inc. Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
WO2007120864A2 (en) * 2006-04-14 2007-10-25 Shire Llc Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse
US20110262427A1 (en) * 2006-12-15 2011-10-27 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
US8349326B2 (en) * 2007-02-20 2013-01-08 Tufts University Methods and systems for multi-antibody therapies
WO2009059972A2 (en) * 2007-11-05 2009-05-14 Nordic Bioscience A/S Biochemical markers for cvd risk assessment
US8147836B2 (en) * 2007-12-17 2012-04-03 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising MMP-14 binding proteins
US20100310464A1 (en) * 2009-06-09 2010-12-09 Affitech Research As Antibodies

Also Published As

Publication number Publication date
EP3019192A4 (en) 2017-07-05
US20190330370A1 (en) 2019-10-31
CN105555310A (en) 2016-05-04
EP3019192A2 (en) 2016-05-18
JP2016523970A (en) 2016-08-12
CN105555310B (en) 2019-07-23
WO2015006337A2 (en) 2015-01-15
JP6449272B2 (en) 2019-01-09
US10407508B2 (en) 2019-09-10
US11168146B2 (en) 2021-11-09
US20160200830A1 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
WO2015006337A3 (en) Compositions and methods for increasing protein half-life in a serum
AU2016219350A8 (en) Humanized anti-MUC1* antibodies
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
AU2018318303A1 (en) Antigen-binding proteins targeting shared antigens
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
BR112018010891A2 (en) antibodies and antibody fragments for site specific conjugation
MX2019008146A (en) Altered virus.
WO2014059442A3 (en) Antibody based reagents that specifically recognize toxic oligomeric forms of tau
WO2014165082A3 (en) Antibodies and methods of detection
EP3176181A4 (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
AU2016320748A8 (en) Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
WO2013051878A3 (en) Antibody specifically binding to epitope in sema domain of c-met
WO2015073884A3 (en) Glycoengineered antibody compositions
EP3442576A4 (en) High affinity b7-h6 antibodies and antibody fragments
WO2017132562A8 (en) Antigen binding proteins that bind pd-l1
EP3702372A3 (en) Anti-cd40 human antibodies
MX2022006461A (en) Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof.
MX2014005546A (en) Albumin binding antibodies and binding fragments thereof.
EP3255063A3 (en) Antibodies to matrix metalloproteinase 9
AU2018338322A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
WO2015075269A9 (en) Antibodies against ccr9 and applications thereof
WO2018119425A3 (en) Anti-lilrb3 antibodies and methods of use thereof
EP4282881A3 (en) Antibodies against csf-1r
MX2022009915A (en) Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480038652.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14822180

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2016525430

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2014822180

Country of ref document: EP